Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

Summary

This phase II trial studies how well olaparib and ceralasertib (AZD6738) work in treating patients with IDH mutant cholangiocarcinoma or solid tumors. Cancer is caused by changes (mutations) to genes that control the way cells function. Laboratory studies have shown that olaparib and AZD6738 can shrink IDH mutant tumors or stop them from growing. Olaparib and ceralasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2020-01-30

Primary completion

2025-03-12

Completion

2026-07-10

Drugs

Indications